NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

NIH-Sponsored Trial of Lassa Vaccine Opens - Viral Hemorrhagic Disease Can be Fatal & Causes Permanent Hearing Loss ...

Uganda’s Ministry of Health on Friday confirmed an outbreak of the Crimean-Congo hemorrhagic fever (CCHF) in the western ...

Lassa fever vaccine is one step closer to approval. Lassa virus infections, primarily spread by rodents, can cause a fatal ...

The NCDC on Wednesday, confirmed 563 Lassa fever cases out of the 2,960 suspected cases of the disease and 103 deaths as of ...

Uganda's Ministry of Health on Friday confirmed an outbreak of the Crimean-Congo hemorrhagic fever (CCHF) in the ...

An NIH-sponsored clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants.

According to the WHO, symptoms of the disease suggest it belongs to a group of diseases called viral hemorrhagic fevers (VHF), meaning they cause excessive sickness and blood loss. Recognised ...

The situation report of the hemorrhagic fever for Week 10 also showed that the disease has spread to 14 states and 78 local government areas with a Case Fatality Ratio of 18.3 per cent.

The results, published in Science Translational Medicine on Feb. 19, could pave the way to the first treatment or vaccine for Crimean-Congo hemorrhagic fever ... s role in the disease was ...